-
Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
-
BMO Capital Remains Bullish on Rigel Pharma (RIGL); Says Tavalisse Launch is On Track
-
Rigel Pharmaceuticals (RIGL) PT Raised to $10 at BMO Capital Following Q1 Earnings Beat
-
Rigel Pharma (RIGL) Prices 16M Share Common Offering at $3.90/Sh
-
Rigel Announces Pricing Of Public Offering Of Common Stock
-
Rigel Pharma (RIGL) Announces Proposed 15M Share Common Offering
-
Rigel Announces Proposed Public Offering Of Common Stock
-
Rigel Pharmaceuticals (RIGL) PT Raised to $8 at BMO Capital on FDA Approval
-
Rigel Pharmaceuticals (RIGL) Weakness 'Overdone' - BMO
-
BMO Capital Bullish on Rigel (RIGL) into Tavalisse PDUFA
-
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
-
Rigel Pharma (RIGL) Prices 18.1M Share Common Offering at $3.35/Sh
-
Rigel Announces Pricing Of Public Offering Of Common Stock
-
UPDATE: Rigel Pharma (RIGL) to Offer Up to $40M in Common Stock
-
Rigel Announces Proposed Public Offering Of Common Stock
-
UPDATE: Rigel Pharmaceuticals (RIGL) PT Raised to $6 at BMO Capital; Fostamatinib Probability of Success Increases
-
Rigel Pharmaceuticals (RIGL) PT Raised to $5 at BMO Capital; Tavalisse NDA Filing Accepted, Improves Probability of Success to 80%
-
Rigel Pharma (RIGL) Reiterates Outperform Rating and $4 PT on Rigel Pharma (RIGL); 'Focused on Fostamatinib's Pending NDA Submission'
-
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
-
Rigel Pharma (RIGL) Prices 20M Common Stock Offering at $2/Share
-
Rigel Announces Pricing Of Public Offering Of Common Stock
-
Rigel Pharma (RIGL) Plans Offering of Common Stock
-
Rigel Announces Proposed Public Offering Of Common Stock
-
Case for Rigel Pharmaceuticals (RIGL) Fostamatinib Approval Gets Stronger - BMO
-
Rigel Pharmaceuticals (RIGL) PT Raised to $6 at BMO Capital Following Positive ITP Study
-
Notable Analyst Rating Changes 8/1: (OAS) (QGEN) (DLTR) Upgraded; (HOG) (AIV) (CTXS) Downgraded
-
BMO Capital Starts Rigel Pharmaceuticals (RIGL) at Outperform, $4 PT
-
Notable Analyst Rating Changes 06/04: (SDRL) (ALTR) (TOL) Upgraded; (PVH) (RIGL) (CP) Downgraded
-
BMO Capital Downgrades Rigel Pharmaceuticals (RIGL) to Market Perform
-
Rigel (RIGL) Affirms Pricing 13.7M Offering at $9.50/Share
-
Rigel Pharma (RIGL) Announces Common Offering
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform